The proposed mechanisms through which BCL6 and EZH2 may interact in CML cells is shown in Figure 2, and provides a rationale for combined BCL6 and EZH2 inhibition in CML cells. The gene discussed is BCL6; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.